Affiliation:
1. Brain Tumor Research Center, Department of Neurological Surgery, University of California, San Francisco, California
2. Cross Cancer Institute, Edmonton, Alberta
Abstract
Abstract
Twenty-one patients with recurrent malignant central nervous system gliomas were treated with a combination of 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine. Thirteen patients had brain stem gliomas, 3 patients had spinal cord gliomas, 3 patients had thalamic gliomas, and 2 patients had cerebellar astrocytomas. All patients had received radiation therapy, and 4 brain stem patients had also been treated with chemotherapy. Sixteen patients (76%) responded to treatment with either stabilization of disease or improvement. Nine of the 13 patients with brain stem gliomas (71%) had response or stabilization of disease. The median time to tumor progression (TTP) for the brain stem patients who responded or had stabilization of disease was 25 weeks. The median survival from recurrence for the brain stem glioma patients was 27 weeks. Patients with cerebellar, thalamic, and spinal cord tumors did very well, with an 87% response or stabilization of disease and a median TTP of 122 weeks.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Clinical Neurology,Surgery
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Chemotherapy of Brainstem Gliomas;Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy;2018
2. Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma;Neuro-Oncology;2015-11-04
3. Brainstem tumors;Handbook of Clinical Neurology;2012
4. Alkylating Agents;Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures;2010-11-03
5. Brainstem Gliomas;Pediatric Oncology;2010